



■ TEL. : 022 - 6825 2525
■ FAX : 022 - 2405 7708
■ E-Mail : info@naxparlab.com
■ Visit us at: www.naxparlab.com
■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

Date: 10th February, 2025

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001.

Sub: Outcome of Board Meeting and Intimation of Appointment of Independent Director pursuant to Regulation 30, read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Submission of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months Ended December 31, 2024, in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Ref.: Parnax Lab Limited, Script Code- 506128

Dear Sir,

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., **Monday, 10th February, 2025**, at its Registered Office, has inter alia, considered and approved the following decisions:

1. Considered and Approved the Standalone & Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024, along with Limited Review Report thereon.

A Copy of Standalone & Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024, along with Limited Review Report thereon, pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2015, is enclosed herewith.

2. Considered and Approved, on the recommendation of Nomination & Remuneration Committee (NRC), the appointment of Mr. Vijay Kumar Ayare (06383445), as an Additional Director (Non-Executive Independent Director) of the Company w.e.f. 10th February, 2025, pursuant to Section 161 of the Act and who holds office upto the date of the ensuing General Meeting of the Company, subject to the approval of the members in the ensuing General Meeting, and shall not be liable to retire by rotation.

The details required along with brief profile under Regulation 30 of the Listing Regulations read with SEBI circular No. CIR/CFD/ CMD/4/2015 dated September 9, 2015 are given in the enclosed as Annexure I.





- TEL. : 022 - 6825 2525
- FAX : 022 - 2405 7708
- E-Mail : info@naxparlab.com
- Visit us at: www.naxparlab.com
- CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

We, further affirm that Mr. Vijay Kumar Ayare, have not been debarred from holding the office of the Director by virtue of any order of Securities and Exchange Board of India or such other authorities.

The aforesaid information and Financial Results are being made available on the Company's website at www.naxparlab.com

The meeting of the Board of Directors Commenced at 4.00 P.M. and Concluded at 04.45 P.M.

Kindly take on your record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For Parnax Lab Limited

PREET
VIJAY
KUKREJA

Digitally signed
by PREET VIJAY
KUKREJA
Date: 2025.02.10
16:45:49 +05'30'



Preet Kukreja
Company Secretary & Compliance Officer
ACS No.: 56761

Encl: As above



■ TEL. : 022 - 6825 2525
■ FAX : 022 - 2405 7708
■ E-Mail : info@naxparlab.com
■ Visit us at: www.naxparlab.com
■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

ANNEXURE I

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sr. No.	Particulars	Mr. Vijay Kumar Ayare
1.	Reason for change viz. appointment, resignation , removal, death or otherwise	Appointment
2.	Date of appointment/ cessation (as applicable) & term of appointment/re-appointment	10.02.2025 The appointment of Mr. Vijay Kumar Ayare (06383445), as an Additional Director (Non-Executive Independent Director) of the Company w.e.f. 10 th February, 2025, pursuant to Section 161 of the Act and who holds office upto the date of the ensuing General Meeting of the Company, subject to the approval of the members in the ensuing General Meeting, and shall not be liable to retire by rotation.
3.	Brief profile (in case of Appointment)	Mr. Vijay Kumar Ayare is having 50+ years of Experience, and offering service in pharmaceutical and cosmetics manufacturing in Wanbury Group. Mr. Vijay Kumar Ayare is committed to harnessing the growth potential of Wanbury Group by catering to the demands of the industry with professionalism and a differentiated service offering. At the core of Wanbury Group, Mr. Vijay Kumar Ayare is one of the qualified and passionate in management team, who has behind him skill and experience. It is as a result of his diligence and perseverance that Wanbury's prowess in pharmaceutical manufacturing has seen exponential growth and achievement. He is Diligent in Strategy and planning, Deal Evaluation and Structuring.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Vijay Kumar Ayare is not related to any of the Directors and Key Managerial Personnel (KMP) of the Company:

For Parnax Lab Limited

Digitally signed by
PREET VIJAY
KUKREJA
Date: 2025.02.10
16:46:17 +05'30'

Preet Kukreja
Company Secretary and Compliance Officer
ACS No.: 56761





To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8,
Jogani Industrial Complex,
Chunabhatti, Mumbai – 400 022

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Parnax Lab Limited** (“the company”) for the quarter and nine months ended December 31st, 2024 together with the relevant notes thereon (“the Statement”). The Statement being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 ‘Review on Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For C. N. Patel & Co.
Chartered Accountants
Firm’s Registration No.: 112552W

CA Manish Maudhania
Partner
M. No.: 112026



Place: Mumbai
Dated: 10th February, 2025
UDIN: 25112026BMOCQP2319

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN:-L36912MH1982PLC027925

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2024

(Rs. in Lakhs)

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from operations	98.63	153.58	276.77	618.20	573.21	744.04
II	Other income	16.67	18.07	12.46	52.02	42.04	53.50
III	Total Revenue (I+II)	115.30	171.65	289.23	670.22	615.25	797.54
IV	Expenses						
	a) Cost of material consumed	36.67	50.67	54.72	109.43	163.86	231.53
	b) Purchase of stock in trade	6.77	18.38	4.42	136.19	42.16	68.34
	c) Changes in inventories of finished goods, Work in progress and stock in trade	-	-	37.13	-	23.89	-
	d) Employee benefit expenses	25.27	21.55	22.70	67.81	54.40	73.64
	e) Finance costs	0.97	0.20	1.48	1.89	12.37	14.10
	f) Depreciation and amortisation expenses	1.59	1.60	1.46	4.77	4.36	5.83
	g) Other expenses	23.47	43.11	34.75	153.13	93.69	159.41
	Total Expenses (IV)	94.74	135.51	156.66	473.22	394.73	552.85
V	Profit/(loss) before exceptional items and tax (III-IV)	20.56	36.14	132.57	197.00	220.52	244.69
VI	Exceptional items	-	-	-	-	-	-
VII	Profit/(loss) before tax (V-VI)	20.56	36.14	132.57	197.00	220.52	244.69
VIII	Tax expense						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	4.78	9.09	33.87	49.18	55.50	62.34
	c) Short (Excess) provision for tax for earlier years	-	-	-	-	-	-
IX	Profit/ (loss) for the period (VII-VIII)	15.78	27.05	98.70	147.82	165.02	182.35
X	Other comprehensive income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(3.23)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	0.81
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XI	Total other comprehensive income for the period	-	-	-	-	-	(2.42)
	Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)	15.78	27.05	98.70	147.82	165.02	179.93
XIII	Paid-up equity share capital (Face Value of the share Rs. 10)	1,148.56	1,148.56	1,148.56	1,148.56	1,148.56	1,148.56
XIV	Earning per equity share (Not annualised)						
	(1) Basic	0.14	0.24	0.86	1.29	1.44	1.59
	(2) Diluted	0.14	0.24	0.86	1.29	1.44	1.59

Notes-

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 10, 2025
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and nine months ended December 31, 2024
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations, hence Segment Reporting under AS17 is not applicable.
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.
- There are no proceeds of public issue, rights issue, preferential issue, qualified institutions placement, etc., therefore statement on the same is not forming part of this results.
- There are no outstanding defaults on loans and debt securities, therefore statement on the same is not forming part of this results.
- The disclosures of Related Party Transaction is applicable only for half yearly filings, therefore it is not forming part of this results.
- The statement on impact of audit qualifications is applicable only for yearly filings, therefore it is not forming part of this results.

Place : Mumbai
Date : 10-02-2025



By Order of the Board
For Parnax Lab Limited

Mihir P.Shah
Managing Director & CEO
DIN : 00387912



C. N. PATEL & CO.
Chartered Accountants

Plot No. 12, Aradhana, State Bank Colony,
Opp. Tidke Vidyalaya, Katol Road, Nagpur - 440013.
Tel. No. +91 712 2584800, 9922584800
Email ID : info@cnpca.in ☎ : www.cnpca.in

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8, Jogani Industrial Complex,
Chunabhatti, Mumbai – 400 022

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Parnax Lab Limited** (“the Parent”) and **Naxpar Pharma Private Limited** (“the Subsidiary”) (the Parent and its subsidiary together referred to as “the Group”) for the quarter and Nine months ended December 31st, 2024 together with the relevant notes thereon (“the Statement”). The Statement submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The Statement is the responsibility of the Parent’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the standards on Review Engagement (SRE) 2410 ‘Review on Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Parent’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities

Parnax Lab Limited	Holding Company
Naxpar Pharma Private Limited	Subsidiary

5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.


Branch: 201 Metro Avenue, Pereira Hill Road, Off Andheri Kurla Road, Near WEH Metro Station, Mumbai - 400 099.



6. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information in respect of one subsidiary, whose unaudited interim financial results include total revenues of Rs. 3,938.31 lakhs and Rs. 13,440.70 lakhs for the quarter and nine months ended December 31, 2024, total net profit of Rs. 105.44 lakhs and Rs. 713.53 lakhs for the quarter and nine months ended December 31, 2024, total comprehensive income of Rs. 105.44 lakhs and Rs. 713.53 lakhs for the quarter and nine months ended December 31, 2024, as considered in the Statement which has been reviewed by its independent auditor. The independent auditor review reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated above in paragraph 6 above, is not modified with respect to our reliance on the work done and the reports of the other auditors.

For C. N. Patel & Co.
Chartered Accountants
Firm's Registration No.: 112552W


CA Manish Mandhana
Partner
M. No.: 112026



Place: Mumbai
Dated: 10th February, 2025
UDIN: 25112026BMOCQQ2140

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN:-L36912MH1982PLC027925

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2024

(Rs. in Lakhs)

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from operations	4,021.61	4,836.29	5,098.86	13,869.93	14,234.19	18,871.12
II	Other income	18.95	94.95	10.12	125.08	56.86	81.57
III	Total Revenue (I+II)	4,040.56	4,931.24	5,108.98	13,995.01	14,291.05	18,952.69
IV	Expenses						
	a) Cost of material consumed	2,328.65	2,151.92	2,906.07	6,811.13	7,891.03	10,473.53
	b) Purchase of stock in trade	6.76	13.61	-	57.20	45.09	15.02
	c) Changes in inventories of finished goods, Work in progress and stock in trade	(179.01)	300.00	82.54	103.70	(31.63)	(207.11)
	d) Employee benefit expenses	566.54	612.17	580.83	1,820.75	1,725.37	2,372.17
	e) Finance costs	123.11	138.46	135.06	411.32	393.75	534.58
	f) Depreciation and amortisation expenses	178.50	193.60	177.96	555.02	511.98	696.44
	g) Other expenses	871.28	1,034.25	932.65	3,063.74	2,829.47	3,863.09
	Total Expenses (IV)	3,895.83	4,444.01	4,815.11	12,822.86	13,365.06	17,747.72
V	Profit/(loss) before exceptional items and tax (III-IV)	144.73	487.23	293.87	1,172.15	925.99	1,204.97
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	144.73	487.23	293.87	1,172.15	925.99	1,204.97
VIII	Tax expense						
	a) Current Tax	21.00	119.40	27.00	232.00	132.00	193.28
	b) Deferred Tax	2.50	26.39	48.98	78.80	56.04	82.25
	c) Short (Excess) Prov for Tax for Earlier Years	-	-	-	-	-	(33.04)
IX	Profit/ (Loss) for the period (VII-VIII)	121.23	341.44	217.89	861.35	737.95	962.48
X	Minority Interest Profit (Loss)	0.21	0.63	0.24	1.43	1.15	1.56
XI	Profit/ (Loss) after share of Profit (Loss) of Minority Interest	121.02	340.81	217.65	859.92	736.80	960.92
XII	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(25.52)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	6.42
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XIII	Total Other Comprehensive Income for the period	-	-	-	-	-	(19.10)
XIV	Total Comprehensive Income comprising profit and other comprehensive income for the period (IX+XIII)	121.23	341.44	217.89	861.35	737.95	943.38
XV	Total profit/(loss) for the year attributable to:						
	- Owners of the Company	121.02	340.81	217.65	859.92	736.80	960.92



S. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	- Non-controlling interests	0.21	0.63	0.24	1.43	1.15	1.56
XVI	Other Comprehensive income attributable to :						
	- Owners of the Company	-	-	-	-	-	(19.07)
	- Non-controlling interests	-	-	-	-	-	(0.03)
XVII	Total Comprehensive income attributable to:						
	- Owners of the Company	121.02	340.81	217.65	859.92	736.80	941.85
	- Non-controlling interests	0.21	0.63	0.24	1.43	1.15	1.53
XVIII	Paid-up equity share capital (Face Value of the share Rs. 10)	1,148.56	1,148.56	1,148.56	1,148.56	1,148.56	1,148.56
XIX	Earning per equity share (Not Annualised)						
	(1) Basic	1.06	2.97	1.90	7.50	6.43	8.38
	(2) Diluted	1.06	2.97	1.90	7.50	6.43	8.38

Notes-

- 1 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- 2 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 10, 2025.
- 3 The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and nine months ended December 31, 2024.
- 4 EPS for quarter ended is on non annualised basis.
- 5 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations, hence Segment Reporting under AS17 is not applicable.
- 6 Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.
- 7 There are no proceeds of public issue, rights issue , preferential issue, qualified institutions placement, etc., therefore statement on the same is not forming part of this results.
- 8 There are no outstanding defaults on loans and debt securities, therefore statement on the same is not forming part of this results.
- 9 The disclosures of Related Party Transaction is applicable only for half yearly filings, therefore it is not forming part of this results.
- 10 The statement on impact of audit qualifications is applicable only for yearly filings, therefore it is not forming part of this results.

Place : Mumbai
Date : 10-02-2025



By Order of the Board
For Parnax Lab Limited

Mihir P. Shah
Managing Director & CEO
DIN NO: 00387912